Metropolitan Life Insurance CO Janux Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$11.25 - $22.21 $4,252 - $8,395	-378 Reduced 27.35%	1,004 $12,000
Q4 2022 Jun 14, 2023	BUY	$11.1 - $18.26 $4,195 - $6,902	378 Added 37.65%	1,382 $18.2 Million
Q3 2022 Jun 14, 2023	BUY	$10.82 - $16.84 $4,089 - $6,365	378 Added 37.65%	1,382 $18.7 Million
Q2 2022 Jun 20, 2023	BUY	$9.52 - $15.65 $3,598 - $5,915	378 Added 37.65%	1,382 $16,000
Q1 2022 Jun 20, 2023	BUY	$13.24 - $20.24 $5,004 - $7,650	378 Added 37.65%	1,382 $19,000
Q1 2022 Mar 30, 2023	SELL	$13.24 - $20.24 $34,807 - $53,210	-2,629 Reduced 65.54%	1,382 $19,000
Q1 2022 May 12, 2022	SELL	$13.24 - $20.24 $34,807 - $53,210	-2,629 Reduced 65.54%	1,382 $20,000
Q4 2021 Jun 21, 2023	BUY	$15.44 - $27.32 $46,428 - $82,151	3,007 Added 299.5%	4,011 $79,000
Q3 2021 Jun 21, 2023	BUY	$20.7 - $34.69 $62,244 - $104,312	3,007 Added 299.5%	4,011 $86,000
Q3 2021 Mar 30, 2023	BUY	$20.7 - $34.69 $54,420 - $91,200	2,629 Added 190.23%	4,011 $86,000
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $83,027 - $139,141	4,011 New	4,011 $87,000

160

37.2M

70.4K

101K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.